Focus Partners Wealth
NBIX icon

Focus Partners Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Focus Partners Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.1M Sell
71,438
-6,556
-8% -$1.05M 0.01% 718
2026
Q2 		$13.1M Sell
77,994
-2,341
-3% -$347K 0.01% 621
2026
Q1 		$10.6M Buy
80,335
+10,401
+15% +$1.38M 0.01% 703
2025
Q4 		$9.9M Buy
69,934
+4,112
+6% +$596K 0.01% 697
2025
Q3 		$9.24M Buy
65,822
+8,645
+15% +$1.17M 0.01% 578
2025
Q2 		$7.19M Buy
57,177
+6,786
+13% +$778K 0.02% 572
2025
Q1 		$5.57M Sell
50,391
-687
-1% -$87K 0.01% 595
2024
Q4 		$6.97M Buy
51,078
+4,420
+9% +$547K 0.02% 542
2024
Q3 		$5.38M Buy
46,658
+782
+2% +$107K 0.02% 544
2024
Q2 		$6.32M Buy
45,876
+397
+0.9% +$54.4K 0.02% 457
2024
Q1 		$6.27M Buy
45,479
+5,058
+13% +$691K 0.05% 281
2023
Q4 		$5.33M Buy
+40,421
New +$4.65M 0.07% 224

Other funds holding NBIX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Focus Partners Wealth's NBIX Position: Q3 2026 in Review

Focus Partners Wealth reduced its Neurocrine Biosciences (NBIX) stake by 8.4% in Q3 2026, selling an estimated $1.05M and leaving 71,438 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #718.

Focus Partners Wealth first reported a position in NBIX in Q4 2023 and has held it in 12 quarters since. The position peaked at $13.1M in Q2 2026. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Focus Partners Wealth held 71,438 shares of Neurocrine Biosciences worth $10.1M as of Q3 2026.
  • Focus Partners Wealth sold 6,556 Neurocrine Biosciences shares in Q3 2026, an estimated $1.05M.
  • Neurocrine Biosciences made up 0.01% of Focus Partners Wealth's portfolio in Q3 2026, its #718 holding.
  • Focus Partners Wealth first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 12 quarters since.
  • Focus Partners Wealth's Neurocrine Biosciences position peaked at $13.1M in Q2 2026.
  • 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Focus Partners Wealth's 13F filing for Q3 2026, filed 12 Nov 2026.